# US 2003/0212082 A1 · Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212082 A1
- Document ID: US20030212082A1
- Status: Published application
- Kind: A1
- Application number: 10/343,587
- Filed: 2003-01-31
- Published: 2003-11-13
- Earliest claimed: 2003-01-31
- Assignees: University of Virginia Patent Foundation
- Inventors: Joel Linden; Amy L. Tucker; Richard Price; Rebecca Youkey
- Web page: https://patentgrep.com/patent/US20030212082A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/38: having sulfur as a ring hetero atom
- A61K 31/381: having five-membered rings
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/16: Masculine contraceptives
- A61P 15/18: Feminine contraceptives
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Angiogenesis is manipulated by administration of selective adenosine A1 allosteric enhancers can be administered in an amount effective to induce angiogenesis at a desired location for treating conditions in which increased angiogenesis is desired, such as stroke, heart disease, and peripheral vascular disease. Selective A1 antagonists can be administered in an amount effective to inhibit angiogenesis at a desired location for treating conditions in which decreased angiogenesis is desired , such as for treating tumors, diabetic retinopathy, inflammatory diseases such as rheumatoid arthritis and psoriasis.

## Claims

### Claim 1

A method of inhibiting angiogenesis comprising administering to a subject in need thereof an effective angiogenesis inhibiting amount of a selective adenosine A1 receptor antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein said selective adenosine A1 receptor antagonist is VVRC-0571.

### Claim 3

A method of treating a condition for which angiogenesis is implicated, comprising administering to a subject in need thereof an effective angiogenesis inhibiting amount of a selective adenosine A1 receptor antagonist.

### Claim 4 (depends on 3)

The method of claim 3, wherein said condition is tumor growth, diabetic retinopathy or an inflammatory disease.

### Claim 5

A composition for inhibiting angiogenesis comprising an effective angiogenesis inhibiting amount of a selective adenosine A1 receptor antagonist and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said selective adenosine A1 receptor antagonist is WRC-0571.

### Claim 7

A method of inducing angiogenesis comprising administering to a subject in need thereof an effective angiogenesis inducing amount of a selective adenosine A1 receptor allosteric enhancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein said selective adenosine A1 receptor allosteric enhancer is PD 81,723.

### Claim 9 (depends on 8)

The method of claim 8, further comprising administration of an adenosine A1 receptor agonist.

### Claim 10 (depends on 9)

The method of claim 9, wherein said adenosine A1 receptor agonist is cyclopentyadenosine.

### Claim 11

A method of treating an ischemic disease, comprising administering to a subject in need thereof an effective angiogenesis inducing amount of a selective adenosine A1 receptor allosteric enhancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein said selective adenosine A1 receptor allosteric enhancer is PD 81,723.

### Claim 13 (depends on 12)

The method of claim 12, further comprising administration of an adenosine Al receptor agonist.

### Claim 14 (depends on 13)

The method of claim 13, wherein said adenosine A1 receptor agonist is cyclopentyadenosine.

### Claim 15 (depends on 11)

The method of claim 11, wherein said disease is heart disease, stroke or peripheral vascular disease.

### Claim 16

A composition for inducing angiogenesis comprising an effective angiogenesis inducing amount of a selective adenosine A1 receptor allosteric enhancer and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The composition of claim 16, wherein said selective adenosine A1 receptor allosteric enhancer is PD 81,723.

### Claim 18 (depends on 17)

The composition of claim 17, further comprising an adenosine A1 receptor agonist.

### Claim 19 (depends on 18)

The composition of claim 18, wherein said adenosine A1 receptor agonist is cyclopentyadenosine.

### Claim 20 (depends on 11)

The composition of claim 11, wherein said disease is heart disease, stroke or peripheral vascular disease.

### Claim 21

A composition for inducing angiogenesis comprising an effective angiogenesis inducing amount of a synergistic combination of a selective adenosine A1 receptor allosteric enhancer and an adenosine A1 receptor agonist in a pharmaceutically acceptable carrier.
